Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 6/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 3/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22815097 | 0.92 | MEN1 (0.33) | MEN1KMT2ARAB9ADPP4DPP8 | |
| SCHEMBL21344232 | 0.90 | RAB9A (0.32) | MEN1KMT2ARAB9ADPP4MLNR | |
| SCHEMBL22815072 | 0.89 | RAB9A (0.31) | MEN1KMT2ARAB9AKDM1APOLB | |
| SCHEMBL21343962 | 0.89 | RAB9A (0.35) | KMT2ARAB9ADPP4DPP8DPP9 | |
| SCHEMBL21343228 | 0.86 | — | — | |
| SCHEMBL21343213 | 0.83 | MITF (0.41) | MEN1KMT2ARAB9AMITFKDM1A | |
| SCHEMBL21343961 | 0.81 | MIF (0.36) | KDM1ADPP4DPP8DPP9POLB | |
| SCHEMBL21344400 | 0.77 | GPR119 (0.43) | MEN1KMT2ARAB9AMDM2 | |
| SCHEMBL21344273 | 0.75 | RORC (0.35) | KDM1ADPP4DPP8 | |
| SCHEMBL21343220 | 0.73 | MITF (0.38) | MEN1KMT2ARAB9AMITFKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399262-A1 | COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER | PI THERAPEUTICS LTD (IL) | 2020-12-24 | — | — | US | disclosed |
| WO-2019171379-A1 | COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER | PI THERAPEUTICS LTD. (IL) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399262-A1 | COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER | ATG7, SQSTM1, UBQLN1 | MEN1 3782/4885KMT2A 2402/4885RAB9A 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.